Biotech Takeover Favourite Abivax Loses Over 30% as Trial Safety Concerns Eclipse Strong Drug Results 

Abivax, which has spent the past year at the centre of intense takeover speculation, announced that its experimental ulcerative colitis treatment, obefazimod, successfully met both primary and key secondary endpoints in a pivotal Phase III maintenance trial.

French biotechnology company Abivax has suffered a dramatic market setback after investors erased more than 30 per cent of its value despite the company reporting positive late-stage results for its flagship bowel disease treatment. The sharp decline highlights the increasingly complex relationship between scientific success and investor confidence in the global biotech sector. 

Abivax, which has spent the past year at the centre of intense takeover speculation, announced that its experimental ulcerative colitis treatment, obefazimod, successfully met both primary and key secondary endpoints in a pivotal Phase III maintenance trial. The study demonstrated strong remission rates among patients with moderate to severe ulcerative colitis, reinforcing the drug’s potential to become a major new therapy in the inflammatory bowel disease market. 

Ordinarily, such results would be expected to drive a biotechnology company’s valuation higher. Instead, investors responded by aggressively selling the stock, sending shares tumbling and wiping billions from the company’s market capitalisation. The reaction was driven not by doubts over the drug’s effectiveness, but by concerns surrounding several cancer cases reported during the study. Although investigators concluded that the cases were unrelated to treatment, the disclosure prompted questions about long-term safety risks and future regulatory scrutiny. 

The market response illustrates a recurring challenge for biotech companies developing therapies for chronic diseases. In areas such as inflammatory bowel disease, where patients often require long-term treatment, investors place enormous weight on safety data. Even isolated adverse events can alter perceptions of commercial viability, particularly when a company’s valuation has already risen sharply on expectations of future success. 

Abivax’s rise over the past twelve months has been remarkable. Positive clinical data released in 2025 transformed the company from a relatively modest biotechnology firm into one of Europe’s most closely watched drug developers. Its valuation surged as investors anticipated that obefazimod could become a significant competitor in the rapidly expanding market for ulcerative colitis treatments. The momentum also fuelled persistent takeover rumours involving major pharmaceutical groups seeking access to promising late-stage assets. 

Those acquisition rumours intensified throughout early 2026, with market speculation linking Abivax to several large pharmaceutical companies. While the company repeatedly denied reports of formal negotiations, investors viewed its clinical programme as an attractive strategic asset for larger drugmakers seeking growth opportunities in immunology and gastrointestinal medicine. 

What makes the latest share price collapse particularly striking is that many analysts continue to view the trial’s efficacy data as exceptionally strong. The study delivered remission rates that compared favourably with existing therapies and met all major clinical objectives. Some market observers described the results as close to a best-case outcome from an effectiveness standpoint. Yet in biotechnology, safety concerns often outweigh efficacy achievements when investors assess long-term commercial prospects. 

Looking ahead, Abivax intends to advance towards regulatory submissions, with plans to seek approval for obefazimod in the United States later in 2026. The company is also expanding development into Crohn’s disease, another major inflammatory bowel condition that could significantly broaden the treatment’s commercial opportunity if future studies prove successful. 

For investors, the episode serves as a reminder that biotechnology valuations are often driven as much by perception and risk management as by scientific achievement. Abivax remains in possession of a potentially transformative medicine, but the market’s reaction demonstrates how quickly sentiment can shift when uncertainty enters the discussion. 

The company’s challenge now is clear: convince regulators, investors and potential strategic partners that the safety concerns do not undermine the long-term promise of obefazimod. Until that confidence is restored, Abivax may find that even strong clinical victories are not enough to prevent sharp swings in market value.